The forecast for peptic ulcer and gastro-oesophageal reflux diseases (GORD) medicine use in the UK shows a consistent upward trend. From 2024 to 2028, there is an increase in the defined daily dosage units per thousand persons per day, with the values projected to grow from 125.3 in 2024 to 133.2 in 2028.

Year-on-year comparisons suggest a steady growth pattern, with a notable compound annual growth rate (CAGR) across the forecast period. Although 2023 data is not explicitly provided, these forecasts indicate a continuation of previous growth trends.

Looking ahead, key trends to monitor include:

Potential implications of emerging healthcare technologies that might influence diagnosis and treatment.
Policy changes within the NHS affecting drug prescriptions.
Increased public awareness and possible lifestyle changes that could impact GORD prevalence.